This joint venture represents an important milestone in the growth journey of both Mölnlycke and Zhende Medical. By joining forces, we are strengthening our presence in China, expanding our wound care portfolio and significantly enhancing our go-to-market capabilities to better serve more customers and patients.

This partnership demonstrates the strength, resilience and long‑term ambition of both companies. By combining our complementary capabilities and deep market knowledge, we are well positioned to meet the growing demand for advanced wound care solutions in China.

Existing clinical research shows that changing gloves after placental delivery, before final closure, reduces surgical site infection rates. Our analysis of this simple change in practice can reduce costs and release capacity for NHS maternity services by reducing hospital readmissions and community follow-up. It is an effective way to reduce spending and utilise resources more efficiently while also improving maternal outcomes.

With more women undergoing major surgery, the risk of complications is rising. Cesarean sections carry some of the highest rates of surgical site infection. This study shows that something as simple as changing gloves before wound closure can make a real difference for mothers and maternity care services. Our Biogel® gloves are designed to make that best practice easy and seamless, so clinicians can stay focused on what matters most: caring for patients,

2025 proved that focused execution and staying close to customers drive results, especially in a turbulent external environment. We’re growing our core business, conquering new markets and transforming how we operate, all while supporting healthcare systems under tremendous pressure to deliver better, more sustainable care.

Chronic wounds are preventable, yet patients continue to suffer because care is fragmented and intervention comes too late. By prioritising prevention, strengthening clinician training and building integrated pathways, Europe can dramatically improve outcomes and reduce avoidable burden on patients and healthcare systems. This white paper provides a clear roadmap, now it’s time for policymakers to act.

Reaching 100 million trays is far more than a production milestone. It represents a meaningful contribution to many millions of procedures in operating rooms worldwide. We are incredibly proud of the role we play in supporting healthcare systems and improving patient outcomes every single day.

We are proud to be part of this pioneering initiative. Our purpose is to revolutionise care for people and planet. Supporting The Patent Bay is a powerful way to help turn that purpose into action.

The Patent Bay was founded to accelerate progress through open knowledge and shared innovation. Mölnlycke Health Care’s decision to share smarter patient risk scoring highlights the power of collaboration—enabling better care and advancing healthcare for all. It’s a clear reminder that sharing drives meaningful progress for people, society and the planet.  

We invested in a new location with the aim to prepare Mölnlycke for the future, with an office conceived to meet the demands of a modern workplace. Our new headquarters was designed to empower collaboration, wellbeing, and innovation – and the strong results from the Leesman survey show we’re delivering on that promise.

This review of the clinical literature confirms the risks of undetected glove breaches and the value of double gloving with indicator systems. With solutions like the Biogel® Indicator System, Mölnlycke aims to provide comfort and confidence—supporting safer surgery for patients and professionals.

This expansion strengthens our US presence and our mission to free patients and caregivers from the burden of wounds. With increased manufacturing capacity, we’re ready to meet the growing needs of our customers and take our US growth to the next level.

This expansion is a very big deal and the result of over a year’s hard work. Besides creating new jobs, it will drive workforce development and bring technological advancements. It’s a win for Mölnlycke, for the local community and for patients. We’re excited about the positive impact it will have locally in Maine and across the broader US healthcare landscape.

Sustainability in healthcare must encompass more than carbon metrics. We need an EU framework that evaluates sustainability holistically across the full lifecycle of medtech products and services.

We are delighted to welcome Filippa to the Mölnlycke Board. Her energy, expertise and experience, as well as her strategic vision, will be a tremendous asset to Mölnlycke as we continue to advance our growth journey.

I am honoured to join the Mölnlycke Board at such a pivotal time. The company has been experiencing strong growth in a healthcare landscape that is continuously evolving. I very much look forward to working with the team to help fulfil the company’s purpose to revolutionise care for people and planet.

We’re proud to open the doors of our new HQ for this special evening. Our move to GoCo Health Innovation City was driven by our ambition to foster partnerships to speed up innovation towards sustainable healthcare; and this was echoed by the panel who spoke about the importance of collaboration to drive true change that benefits both people and planet.

This wonderful building is more than just bricks and mortar—it embodies the boldness and passion that define Mölnlycke. We’re excited to be part of a community that shares our vision of smarter, safer and more sustainable healthcare.

This validation represents a critical step in executing our strategy to drive decarbonisation of healthcare. Reaching net zero demands measurable action, close collaboration, and innovation across the entire value chain. Mölnlycke is fully committed to working with its partners, suppliers, and customers to drive progress and deliver concrete outcomes.

The results of this study clearly demonstrate how simple changes to a wound care treatment regime can bring about positive outcomes for both patients and healthcare providers. At a time when healthcare systems and staff are under increasing pressure on both cost and time it is encouraging that there are solutions to help drive efficiencies and improve outcomes for all involved.

This partnership underscores our dedication to the Middle Eastern market and aligns with the Saudi Vision 2030. By expanding our product range and investing locally, we aim to enhance healthcare quality and contribute to regional growth. We extend our gratitude to Tamer Group for their unwavering support and look forward to achieving great milestones together.

At Mölnlycke, we believe that education is a cornerstone of progress in healthcare. The 2025 Future Summit exemplifies our commitment to fostering innovation, enhancing clinical practice, and building partnerships that enable healthcare professionals to improve patient outcomes. We are thrilled to bring together such a diverse and accomplished group of experts to shape the future of wound care.

This is a significant milestone in Mölnlycke’s commitment to halving Scope 1 and 2 greenhouse gas emissions by 2030. It propels us towards our vision of building a sustainable healthcare manufacturing ecosystem.

Our strategic investment in Siren reflects our commitment to integrating into digital ecosystems and pioneering innovative digital solutions that revolutionise healthcare delivery. Helping to prevent wounds from occurring is also in line with Mölnlycke’s Wound Care mission to ‘help free patients from the burden of wounds’ and our ambition to further support healthcare in the post-acute segment.

Our ambition is to transform our business to become a global leader in sustainable healthcare. This award is proof that we are on the right track. We are dedicated to equipping our customers with innovative and sustainable healthcare solutions – for our customers, our employees, our communities and the planet.

The support from Mölnlycke in establishing the centre is grounded in our commitment to ensure equitable access to healthcare for all and the vision we have for achieving sustainable healthcare. A part of this vision is making the centre self-sufficient, and that includes raising the level of knowledge of the local healthcare professionals in the areas where Mölnlycke can offer expertise. Cleft patients continue to be stigmatised and we are delighted to be able to contribute to changing their lives and fully including them in society.

We are excited by our research collaboration with TDG allowing us to be at the forefront of advanced understanding of chronic wounds. This opens up a wealth of opportunities for future innovation in the under resourced and under prioritised area of wound care.

The acquisition of P.G.F. will allow Mölnlycke to expand our Granudacyn business and further develop our growing wound care portfolio. Granudacyn effectively cleanses wounds, which supports healing, ultimately helping to ease the burden of wounds

Mölnlycke’s purpose is to revolutionise care for people and planet. In the Antiseptics business area, we do this by making patient skin decolonisation manageable and motivational. We believe that Steriwave can improve the lives of millions of people, fitting perfectly with our purpose and mission. The ability to rapidly eliminate multiple drug-resistant pathogens without generating antimicrobial resistance is key to our sustainability initiative, and complements our Hibiwash® brand skin prep line, enabling us to provide comprehensive ‘nose-to-toes’ decolonisation prior to surgery. Universal decolonisation is now a well-accepted practice to improve surgical outcomes and produce significant cost savings to healthcare systems.

We are excited to be partnering with Mölnlycke Health Care, whose global reach, corporate vision and commitment to sustainable healthcare aligns perfectly with our own core values, purpose and mission. The Mölnlycke collaboration represents a transformative step towards our ambitious plans to combat HAIs and antimicrobial resistance globally. We look forward to working with Mölnlycke in these initial key markets and beyond.

We are very excited to make this strategic investment in MediWound. It aligns with our strategy to bring radical innovations into the wound care space and provide alternative solutions to the more traditional debridement options to improve clinical outcomes and patient experience. This investment will support Mölnlycke’s Wound Care mission to ‘help free patients from the burden of wounds’ and I look forward to this partnership.

We are delighted to have Mölnlycke’s support. This substantial investment will empower us to strengthen our strategic plans, creating significant long-term value for our stakeholders and help to improve standards of care for patients

“To ensure we meet customer demand, geographical expansion is a strategic priority for Mölnlycke Health Care. Increased investment in our existing long-term partnership with Tamer Group will importantly enable healthcare professionals and patients in Saudi Arabia access to our quality products and solutions helping to improve outcomes, and is a step closer to realising the potential of this rapidly growing healthcare market.”

“This investment is key to enabling future growth in the region as outlined in the Saudi Vision 2030 - supporting the regional healthcare ecosystem, including exporting goods to the Middle East and Africa region, whilst developing local skills and expertise.”

“I am delighted to lead this business where Mölnlycke and Tamer will build a strong, long-term successful joint venture, bringing superior health care solutions to our region.”

The state of Kedah is very proud to be the host of Mölnlycke’s new state-of-the-art factory, and in being recognised as a state providing the right prerequisites for sustainable production of high-quality surgical gloves, and in enabling Mölnlycke to live its vision to improve hand performance for health care professionals across the globe – because hands deserve better.

Mölnlycke’s decision to continue and expand its operations here in Kulim is a clear indicator of the successful story of Malaysian manufacturing in particular here in Kedah. In return, Mölnlycke, a global leader within MedTech, will be able to increase its competitiveness on the global market. This is a story of successful cooperation, a win-win, between Mölnlycke – Kulim and Kedah, which is also the story of our two countries. Sweden and Malaysia have a great history of producing win-wins and we will continue to do so.

here is a lot to be proud of when working at Mölnlycke. When future generations look back at our history, I am convinced they will see this day as a milestone – as we take yet another step on our journey to become a global leader in sustainable healthcare production and supply and a leading employer in the global healthcare sector.

The new plant is a key part of our future plans for sustainable growth within the surgical gloves business. It will enable us to expand production to meet projected demand. But the best part is that we will achieve this in a less resource intensive way, at the same time offering a state-of-the-art working environment for our colleagues in Malaysia

The surgical gloves manufacturing process is resource intensive. By partnering with experts in the fields of energy management and water management, we ensure we act to realise our ambition to become a global leader in sustainable healthcare. I am very pleased with the partnerships with ENGIE and Veolia – they are important in bringing to life ‘WeCare’, Mölnlycke’s sustainability transformation agenda for the Gloves business area.

ENGIE is proud to be the chosen long-term sustainability partner to Mölnlycke in accelerating their low-carbon journey in Malaysia. This will be an important milestone for our partnership, helping the Kulim plant use as little energy as possible. More broadly, the project exemplifies how industry players can reap economic benefits by accelerating their energy transition with low-carbon solutions.

Veolia is firmly committed to championing ecological transformation. We are excited to partner with companies like Mölnlycke, who seek to establish sustainable practices and integrate a green mindset into their business. Our team is proud to be part of Mölnlycke's expansion plans in Malaysia and we look forward to more avenues to support their endeavour for greater sustainability and improved performance.

Our aim is to ensure the healthcare professionals we work with in the UK have the tools needed to continue patient care, even in the uncertain times ahead. We see the UK distribution centre as essential to how we operate here in the UK as a way of minimising the impact that wider national and global situations may have on our product supply.

In addition to the immediate benefits with regards to efficient supply chain and reduced carbon footprint, the new UK distribution centre provides new and exciting opportunities for us to explore additional logistical services to benefit customers in the future.

Adding oxygen therapy to our leading range of healing solutions for chronic wounds is a fundamental milestone for Mölnlycke in advancing wound care in this progressive and rapidly developing region

This exciting new technology will help reduce the incidence of serious infection and minimise the unnecessary use of antibiotics.

This is fully in line with where we want to be as a company, and M&J’s strong R&D capabilities combined with Mölnlycke’s end-product knowledge will help us further improve our competitive position within the advanced wound care industry.

We believe that the Mepilex Border Flex dressing may change the way wound care experts practice

'Today, chronic wounds, such as foot ulcers, have a higher mortality rate than both breast cancer and prostate cancer and the real burden of ulcers is not yet fully known or understood. '

Mӧlnlycke’s dedication to pressure injury prevention is an example of our shared commitment with the WOCN Society